A cost-effectiveness analysis of screening for silent atrial fibrillation after ischaemic stroke

Europace

Volumn 17, Issue 2, 2014, Pages 207-214

  Levin, Lars Ake ^a   Husberg, Magnus ^a   Sobocinski, Piotr Doliwa ^b   Kull, Viveka Frykman ^b   Friberg, Leif ^b   Rosenqvist, Marten ^b   Davidson, Thomas ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

Author keywords

Atrial fibrillation; Cost effectiveness; Ischaemic stroke; QALY; Screening; Secondary prevention

Indexed keywords

WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL DECISION MAKING; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ELECTROCARDIOGRAM; HEALTH STATUS; HEART ATRIUM FIBRILLATION; HIDDEN MARKOV MODEL; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SCREENING; SECONDARY PREVENTION; VERY ELDERLY; ASYMPTOMATIC DISEASE; ATRIAL FIBRILLATION; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; ELECTROCARDIOGRAPHY; MASS SCREENING; PROBABILITY; STROKE; SWEDEN;

AGED; ASYMPTOMATIC DISEASES; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; COST-BENEFIT ANALYSIS; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; HUMANS; MARKOV CHAINS; MASS SCREENING; QUALITY-ADJUSTED LIFE YEARS; SECONDARY PREVENTION; STROKE; SWEDEN;

EID: 84922475147     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euu213     Document Type: Article

References (40)

1. Davidson T, Husberg M, Janzon M, Levin L. The cost of thromboembolic events and its prevention among patients with atrial fibrillation. JAFIB 2011;2:1-11.
2. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a populationbased study. Stroke 2005;36:1115-9.
3. Hart RG, Pearce LA, Koudstaal PJ. Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European atrial fibrillation trial and stroke prevention in atrial fibrillation iii trial. Stroke 2004;35:948-51.
4. Baturova MA, Lindgren A, Carlson J, Shubik YV, Bertil Olsson S, Platonov PG. Atrial fibrillation in patients with ischaemic stroke in the Swedish national patient registers: how much do we miss?. Europace 2014;16:1714-9.
5. Barthelemy JC, Feasson-Gerard S, Garnier P, Gaspoz JM, Da Costa A, Michel D, et al. Automatic cardiac event recorders reveal paroxysmal atrial fibrillation after unexplained strokes or transient ischemic attacks. Ann Noninvasive Electrocardiol 2003;8: 194-9.
6. Stahrenberg R, Weber-Kruger M, Seegers J, Edelmann F, Lahno R, Haase B, et al. Enhanced detection of paroxysmal atrial fibrillation by early and prolonged continuous Holter monitoring in patients with cerebral ischemia presenting in sinus rhythm. Stroke 2010;41:2884-8.
7. Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke 2013;44:3357-64.
8. Sobocinski P, Anggårdh Roth E, Frykman Kull V, von Arbin M, Wallén H, Rosenqvist M. Improved screening for silent atrial fibrillation after ischaemic stroke. Europace 2012;14:1112-6.
9. Wilson J, Jungner G. Principles and practice of screening for disease. WHO Public Health Paper no. 34. Geneva:World Health Organization; 1968.
10. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005.
11. Swedish Pharmaceutical Benefits Board. General guidelines for economic evaluations. 2003.
12. Doliwa PS, Frykman V, Rosenqvist M. Short-Term ECG for out of hospital detection of silent atrial fibrillation episodes. Scand Cardiovasc J 2009;43:163-8.
13. Hendrikx T, Hornsten R, Rosenqvist M, Sandstrom H. Screening for atrial fibrillation with baseline and intermittent ECG recording in an out-of-hospital population. BMC Cardiovasc Disord 2013;13:41.
14. Davidson T, Husberg M, Janzon M, Oldgren J, Levin LA. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. Eur Heart J 2013;34:177-83.
15. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009;361: 1139-51.
16. Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the chads2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 2011;155:660-7, W204.
17. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012; 125:2298-307.
18. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L, Randomized Evaluation of Long-Term Anticoagulation Therapy I. Newly identified events in the RE-LY trial. New Engl J Med 2010;363:1875-6.
19. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53.
20. Ghathnekar O, Steen-Carlsson K. Kostnader för insjuknande i stroke år 2009-en incidensbaserad studie. Lund: IHE 2012. IHE Rapport 2012:2.
21. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005;293:699-706.
22. Burstrom K, Johannesson M, Diderichsen F. Health-related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy 2001; 55:51-69.
23. Lee HY, Hwang JS, Jeng JS, Wang JD. Quality-Adjusted life expectancy (QALE) and loss of QALE for patients with ischemic stroke and intracerebral hemorrhage: a 13-year follow-up. Stroke 2010;41:739-44.
24. Bruggenjurgen B, Rossnagel K, Roll S, Andersson FL, Selim D, Muller-Nordhorn J, et al. The impact of atrial fibrillation on the cost of stroke: The Berlin Acute Stroke Study. Value Health 2007;10:137-43.
25. Luengo-Fernandez R, Gray AM, Rothwell PM. Population-based study of determinants of initial secondary care costs of acute stroke in the United Kingdom. Stroke 2006;37:2579-87.
26. Burstrom K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the eq-5d. Qual Life Res 2001;10:621-35.
27. Statistics Sweden. 2010.
28. Henriksson KM, Farahmand B, Johansson S, Asberg S, Terent A, Edvardsson N. Survival after stroke-The impact of CHADS2 score and atrial fibrillation. Int J Cardiol 2010;141:18-23.
29. Fries JF, Koop CE, Beadle CE, Cooper PP, England MJ, Greaves RF, et al. Reducing health care costs by reducing the need and demand for medical services. The health project consortium. New Engl J Med 1993;329:321-5.
30. Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005;9:iii-iv, ix-x, 1-74.
31. van Kempen BJ, Spronk S, Koller MT, Elias-Smale SE, Fleischmann KE, Ikram MA, et al. Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals. J AmColl Cardiol 2011;58: 1690-701.
32. Quaglini S, Rognoni C, Spazzolini C, Priori SG, Mannarino S, Schwartz PJ. Costeffectiveness of neonatal ECG screening for the long QT syndrome. Eur Heart J 2006;27:1824-32.
33. Wang YC, Cheung AM, Bibbins-Domingo K, Prosser LA, Cook NR, Goldman L, et al. Effectiveness and cost-effectiveness of blood pressure screening in adolescents in the united states. J Pediatr 2011;158:257-64. e251-257.
34. Friberg L, Engdahl J, Frykman V, Svennberg E, Levin LÅ , Rosenqvist M. Population screening of 75- And 76-year-old men and women for silent atrial fibrillation (STROKESTOP). Europace 2013;15:135-40.
35. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013;110:213-22.
36. Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, et al. Feasibility and cost effectiveness of stroke prevention through community screening for atrial fibrillation using iphoneECGin pharmacies.The search-Af study. Thromb Haemost 2014; 111:1165-76.
37. Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-Analysis. Stroke 2014;45:520-6.
38. Friberg L, Engdahl J, Frykman V, Svennberg E, Levin LA, Rosenqvist M. Population screening of 75- And 76-year-old men and women for silent atrial fibrillation (strokestop). Europace 2013;15:135-40.
39. Barrett PM, Komatireddy R, Haaser S, Topol S, Sheard J, Encinas J, et al. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. Am J Med 2014;127:95 e11-97.
40. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/ EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012;14:528-606.